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Introduction
Esophageal cancer is estimated to affect more than 
450,000 individuals worldwide with an annually increasing 
incidence. Despite the advancement in the management of 
those patients, the prognosis has not changed; the overall 
5-year survival of patients with resectable esophageal cancer 
remains disappointing, ranging from 15% to 34% (1-3). 
The oncological management of esophageal cancer 
with the introduction of neo-adjuvant chemoradiation 
first started in the early 1980s. Several studies including 
randomized controlled trials have shown an improved 
survival with use of neoadjuvant chemoradiotherapy (NCRS) 
in esophageal cancer suitable for resection especially for 
squamous cell histological subtype with reported 3-year 
survival of 14% and a 5-year survival of 13% (4-6). 
Definitive combined chemoradiotherapy in the absence 
of intended surgical resection has been suggested as a 
treatment option in patients with poor performance status, 
and also those who opt not to have surgery. Previous 
randomized controlled trials have demonstrated that 
surgical resection in treatment of esophageal squamous 
cell carcinoma does not improve overall survival when 
compared with definitive chemoradiotherapy (7,8). 
However, there is an associated mortality of 18% patients 
in this frail patient cohort, with a 40–75% local recurrence 
rates following definitive chemoradiotherapy. The subset of 
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patients with disease recurrence that will be considered for 
salvage esophagectomy (9,10). 
Radiotherapy to the thoracic and abdominal cavities has an 
effect on surgical planes along with systemic effects of cardiac 
and pulmonary toxicity. These factors and the underlying 
physiology of these patients ensure salvage esophagectomy is 
a high-risk procedure. This has previously been reflected by 
the increased mortality and morbidity rates associated with 
salvage esophagectomy in small case series. 
The objectives of this review are to compare both the short- 
and long-term clinical outcomes from salvage esophagectomy 
following definitive chemoradiotherapy In comparison to those 
receiving planned esophagectomy with NCRS for esophageal 
cancer from published literature. 
Methods
A systematic literature search of MEDLINE (January 1950–
October 2016), EMBASE (January 1974–October 2016), 
Web of Science (January 1990–June 2016) and the Coch-
rane Library databases was performed. The search terms 
‘(o)esophagectomy’, ‘salvage’, ‘definitive’, ‘neoadjuvant’, 
‘(o)esophageal cancer’ and ‘chemoradiotherapy’ and the 
medical subject headings (MeSH) ‘(o)esophagectomy’, 
‘(o)esophageal neoplasm’, ‘chemoradiotherapy’, ‘salvage 
therapy’, ‘evidence-based medicine’ and ‘evidence-based 
practice’ were used in combination with the Boolean 
operators AND or OR.
Abstracts of citations identified by the search were 
scrutinized by two independent observers (Sheraz Markar 
and Sara Jamel) to determine eligibility for inclusion in this 
pooled analysis. Publications were included if they met all 
of the following criteria: 
(I) Patients with diagnosis of esophageal cancer; 
(II) Surgical treatment was utilized with a curative intent; 
(III) The study compared cl inical  outcome from 
esophagectomy after definitive chemoradiotherapy 
( sa lvage )  to  e sophagec tomy p lanned  a f te r 
neoadjuvant chemo-radiotherapy (NCRS); 
(IV) Only articles published from 1995 onwards were 
included in this analysis (this was to ensure that the 
studies included reflected current surgical and peri-
operative management of esophageal cancer);
(V) The study used only primary data and was not an 
editorial or systematic review.
The primary outcome was overall survival. Secondary 
outcomes were the incidence of post-operative mortality 
[defined as death during hospital admission (in-hospital) or 
within 30 days of surgery (30-day)], overall postoperative 
morbidity, specifically anastomotic leak and pulmonary 
complications (including pneumonia, pneumothorax and 
respiratory failure), and positive resection margin.
Statistical analysis 
Overall survival
The logarithm of the hazard ratio (HR) with 95% 
confidence interval (95% CI) was used as the primary 
summary statistic. To estimate HR and its variance, this 
was extracted from the study directly or required additional 
calculation depending on the method of data being 
presented: annual mortality rates, survival curves, number 
of deaths or percentage freedom from death (11). 
Other outcomes
Data from eligible trials were entered into a computerized 
spreadsheet for analysis. Statistical analysis was performed 
using StatsDirect 2.5.7 (StatsDirect, Altrincham, UK). 
Meta-analysis of data was conducted using a random 
effects model. POR, with 95% CI, were calculated for 
the effect of salvage esophagectomy on discrete variables 
(postoperative mortality, morbidity, anastomotic leak, 
pulmonary complications and positive resection margin). 
Pooled outcome measures were determined using random-
effects models as described by DerSimonian and Laird (12). 
Heterogeneity among trials was assessed by means of the 
I2 inconsistency test. This was graded as low (I2<25%), 
moderate (I2=25–75%) or high (I2>75%). The Egger test 
was used to assess the funnel for significant asymmetry 
indicating possible publication or other biases. The 
significant level was set at P<0.05. 
Results
Study and patient demographics 
Eleven studies were identified in the initial literature search 
to meet inclusion criteria (Figure 1) (13-23). After screening, 
one further publication (23), was excluded as this institution 
published their outcomes in a follow-up publication, which 
was included in the analysis (16). Therefore, ten comparative 
studies were included in this pooled final analysis (13-22). In 
total 1,906 patients were included, 563 in the salvage group 
and 1,343 in the NCRS group. As expected the majority 
of patients were esophageal squamous cell carcinoma, 
with a large degree of heterogeneity observed in tumor 
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Records identified through database 
searching (n=225)
Additional records identified through 
other sources (n=50)
Records after duplicates removed (n=234)
Records screened (n=234)
Full-text articles assessed for 
eligibility (n=30)
Studies included in qualitative 
synthesis (n=11)
Studies included in quantitative 
synthesis (meta-analysis) (n=11)
Full-text articles excluded, with 
reasons (n=19)
Records excluded (n=204)
Figure 1 PRISMA search strategy.
Table 1 Tumor location and histological subtype for studies included
Study
Patient 
number 
(salvage)
Patient 
number 
(NCRS)
Tumor location (%) Histological subtype (%)
Upper 
(SALV)
Upper 
(NCRS)
Middle 
(SALV)
Middle 
(NCRS)
Lower 
(SALV)
Lower 
(NCRS)
Adeno 
(SALV)
Adeno 
(NCRS)
SCC 
(SALV)
SCC 
(NCRS)
Miyata 33 115 30 42 55 43 15 15 – – – –
Morita 27 197 33.3 26.9 33.3 48.2 33.3 24.9 – – – –
Takeuchi 25 40 32 15 60 72.5 8 12.5 – – 100 100
Markar 308 540 19.2 20.1 40.9 40.6 39.9 39.2 62.7 64.9 35.4 32.8
Marks 65 521 – – – – 95.4 97.7 100 100 – –
Nakamra 27 28 3.7 17.8 62.9 60.7 22.2 21.4 – – – –
Swisher 13 99 30.7 1 23 19 46 80 46 75 54 22
Smithers 14 53 7 0 29 9 64 91 64 89 36 9
Farinella 16 32 50 9.4 18.8 21.8 31.2 68.8 12.5 43.8 87.5 53.1
Tomimaru 24 26 20.8 34.6 54.2 42.3 25 23.1 0 0 100 100
Chao 27 191 29.6 20.9 51.8 54.5 18.5 24.6 – – – –
Salv, salvage esophagectomy; NCRS, neoadjuvant chemoradiotherapy.
location (Table 1). Similarly, heterogeneity was detected in 
the analysis of the radiation dosage used in the context of 
definitive chemoradiotherapy, and the timing of salvage 
surgery following definitive chemoradiotherapy (Table 2). 
A summary of clinical outcomes of reported rate of post-
operative morbidity and mortality is shown in Table 3.
Outcome measures
Overall survival (Figure 2)
Pooled analysis of eight studies (13-16,18-21) included 
1,711 patients, 506 in the salvage group and 1,205 in the 
NCRS group. The median follow-up period ranged from 60 to 
72 months. The pooled analysis demonstrated no significant 
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Table 2 Total dose of radiation and average time to surgery for all studies
Study Salv group No. NCRS group No.
Total radiation dose (Gy) Average time to surgery (days)
Salv NCRS Salv NCRS
Miyata 33 115 59.8 39.9 249 38.3
Morita 27 197 >60 38 – –
Takeuchi 25 40 >50 <50 – –
Markar 308 540 – – – –
Marks 65 521 50 48 216 50
Nakamra 27 28 63 38 111 28
Swisher 13 99 56.7 41.4 – –
Smithers 14 53 60 35 196 28
Farinella 16 32 57.7 45 – –
Tomimaru 24 26 62 40 180 40
Chao 27 191 – – – –
Salv, salvage esophagectomy; NCRS, neoadjuvant chemoradiotherapy.
Table 3 Clinical outcomes for all studies included 
Study
Postoperative  
mortality (%)
Postoperative  
morbidity (%)
Anastomotic  
leak (%)
Pulmonary  
complications (%)
R1/2 resection  
margin (%)
Salv NCRS Salv NCRS Salv NCRS Salv NCRS Salv NCRS
Miyata 12 4 – – 39 13 – – 12 12
Morita 7.4 2 59 40 37 23 29.6 14.7 29.6 22.8
Takeuchi 5 8 – – 24 – 44 25 20 22.5
Markar 8.4 9.3 63.6 58.9 17.2 10.7 42.9 40.9 12.7 11
Marks 4.6 5.2 – – 18.5 11.3 23.1 17.9 9.2 5.4
Nakamra 3.7 0 – – 3 1 22.2 14.3 33 39
Swisher – 6 – – 38 7 – – – –
Smithers 7 2 79 62 14 8 57 30 – –
Farinella 0 0 44 37.5 25 3 37.5 28 19 3
Tomimaru 12.5 0 50 23.1 11.5 11.5 20.8 11.5 33.3 11.5
Chao 22.2 7.9 – – 14.8 1.1 33.3 11.5 37.1 15.7
Salv, salvage esophagectomy; NCRS, neoadjuvant chemoradiotherapy.
difference between salvage and NCRS groups in overall 
survival (HR =1.17; 95% CI, 0.94–1.46, P=0.148). There was 
no evidence of significant statistical heterogeneity (I2=0%), 
however there was significant bias (Egger =3.73, P=0.027). 
Postoperative mortality (Figure 3)
Pooled analysis of nine studies (13-16,18-22) included 
1,711 patients, 506 in the salvage group and 1,205 in the 
NCRS group. There was no significant difference between 
the groups in postoperative mortality (POR =1.12; 95% 
CI, 0.52–2.41, P=0.775). There was moderate statistical 
heterogeneity (I2=44.6%), however no significant evidence 
of bias (Egger =1.32, P=0.111).
Postoperative morbidity (Figure 4)
The pooled analysis of five studies (14-16,18,20), revealed 
a significant increased incidence of overall postoperative 
morbidity in the salvage group (POR =1.30; 95% CI, 1.00–
1.67, P=0.046). There was no evidence of significant statistical 
heterogeneity (I2=0%), or bias (Egger =1.23, P=0.126). 
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Figure 2 Forrest plot showing no significant difference between the groups in overall survival (HR =1.17; 95% CI, 0.94–1.46, P=0.148). 
HR, hazard ratio.
Figure 3 Forrest plot showing no significant difference between the groups in postoperative mortality (POR =1.12; 95% CI, 0.52–2.41, 
P=0.775). POR, pooled odds ratios.
Summary meta-analysis plot [random effects]
0.5 1 2 5 10
combined 1.17 (0.94, 1.46)
Tacheuchi 1.40 (0.75, 2.63)
Smither 1.06 (0.60, 1.89)
Nakamura 1.25 (0.73, 2.14)
Morita 1.05 (0.57, 1.95)
Marks 1.21 (0.63, 2.32)
Markar 0.98 (0.57, 1.68)
Farinella 2.24 (0.93, 5.40)
Chao 1.02 (0.54, 1.92)
* ratio (95% confidence interval)
Odds ratio meta-analysis plot [random effects]
0.01 0.1 0.2 0.5 1 2 5 10 100
Tomimaru 8.63 (0.46, infinity)
Tacheuchi 1.65 (0.11, 24.05)
Smither 11.89 (0.10, infinity)
Nakamura 1.04 (0.01, 84.50)
Morita 3.86 (0.33, 28.29)
Marks 1.07 (0.12, 4.78)
Markar 0.72 (0.40, 1.27)
Farinella * (excluded)
Chao 0.24 (0.06, 0.94)
combined [random] 1.12 (0.52, 2.41)
odds ratio (95% confidence interval)
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Figure 4 Forrest plot showing an increase in postoperative morbidity following salvage esophagectomy (POR =1.30, 95% CI, 1.00–1.67, 
P=0.046). POR, pooled odds ratios.
Odds ratio meta-analysis plot [random effects]
0.2 0.5 1 2 5 10 100
Smither 2.22 (0.50, 13.74)
Morita 2.17 (0.89, 5.45)
Marks 1.43 (0.79, 2.54)
Markar 1.12 (0.80, 1.57)
Farinella 1.30 (0.32, 5.15)
combined [random] 1.30 (1.00, 1.67)
odds ratio (95% confidence interval)
Odds ratio meta-analysis plot [random effects]
0.1 0.2 0.5 1 2 5 10 100 1000
Tomimaru 3.16 (0.44, 35.83)
Tacheuchi 0.95 (0.24, 3.46)
Smither 2.04 (0.16, 16.10)
Nakamura 2.38 (0.44, 16.26)
Morita 1.93 (0.73, 4.82)
Miyata 2.26 (0.90, 5.55)
Marks 1.77 (0.81, 3.60)
Markar 1.73 (1.06, 2.86)
Farinella 10.33 (0.86, 524.75)
Chao 2.40 (0.30, 28.64)
combined [random] 1.88 (1.41, 2.51)
odds ratio (95% confidence interval)
Figure 5 Forrest plot showing an increase in anastomotic leak following salvage esophagectomy (POR =1.88; 95% CI, 1.41–2.51, P<0.001). 
POR, pooled odds ratios.
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Anastomotic leak (Figure 5)
Anastomotic leak was reported in all included studies (13-22), 
which showed a significant increase in the salvage group 
(POR =1.88; 95% CI, 1.41–2.51, P<0.001). There was no 
evidence of significant statistical heterogeneity (I2=0%), or 
bias (Egger =0.70; P=0.141).
Pulmonary complications (Figure 6)
All ten studies reported the incidence of postoperative 
pulmonary complications (13-22), which showed no 
significant differences between the groups (POR=1.24, 95% 
CI, 0.83–1.86, P=0.292). There was evidence of moderate 
statistical heterogeneity (I2=49.3%), however no significant 
evidence of statistical bias (Egger =0.19, P=0.834). 
Positive resection margin (Figure 7)
Nine studies reported the incidence of positive (R1/R2) 
resection margin (13-19,21,22). Pooled analysis showed 
no significant difference between the groups in positive 
resection margin incidence (POR=1.29, 95% CI, 0.94–1.76, 
P=0.114). There was no evidence of significant statistical 
heterogeneity (I2=0%), or bias (Egger =0.93, P=0.232).
Discussion
The present study is the largest meta-analysis to date 
conducted to evaluate the efficacy of undertaking salvage 
esophagectomy following definitive chemoradiotherapy 
compared to those undergoing planned esophagectomy 
with NCRS. The results of this meta-analysis suggest the 
salvage esophagectomy is comparable to NCRS in terms 
of postoperative mortality, pulmonary complications, R1/2 
resection margin and overall survival. However, salvage 
was associated with a significant increase in postoperative 
morbidity and specifically anastomotic leak when compared 
with NCRS. 
It is important to consider the limitations of this meta-
analysis in the interpretation of the results gained. Firstly 
there is a large degree of heterogeneity between the studies 
included, especially regarding histological subtype of 
tumor. Further, the indication for salvage esophagectomy 
as persistent or recurrent disease following definitive 
chemoradiotherapy was not defined in the majority of 
studies, which may represent an important confounding 
variable. The proportion of patients with persistent or 
recurrent disease following definitive chemoradiotherapy, 
who were turned down from surgery was not quantified 
in the majority of studies, suggesting the introduction 
of selection bias. Finally, the heterogeneity between the 
studies extends to confounding variables, which may have 
partially influenced some of the results gained from this 
meta-analysis. 
Analysis of short-term outcomes suggested that salvage 
esophagectomy was equivalent to NCRS with the exception 
of anastomotic leak. However it must be emphasized 
that salvage esophagectomy represents one of the more 
complex variants of esophagectomy due to the scarring 
effects of radiotherapy upon the operative field (24). 
Thus previous surgeon volume-outcome effects observed 
for all esophagectomy are likely to be amplified in the 
setting of salvage esophagectomy (25). Suggesting this 
procedure should only be performed in specialized high 
volume esophageal surgical units, with the high level of 
surgical and medical expertise available to manage these 
complex patients. Further the toxic effects of definitive 
chemoradiotherapy may show a dose-response relationship, 
as some studies with total radiation dose up to 60 Gy 
showing an increase in postoperative mortality within the 
salvage group (15). However the improvement in tumor 
response at such high levels of radiotherapy remains unclear, 
and thus the rationale for using such high radiation doses as 
part of definitive chemoradiotherapy is questionable. 
Salvage esophagectomy was associated with an increase in 
anastomotic leak when compared with NCRS. This may be 
in part a reflection of the presumed negative effects that high 
doses of radiotherapy have upon the micro-circulation of the 
gastric conduit, resulting in patchy areas of necrosis impairing 
conduit perfusion and causing anastomotic leak. This further 
suggests the need for salvage esophagectomy to be performed 
by high volume experienced esophageal surgeons practicing 
in high volume centers, with the appropriate infrastructure to 
rescue patients who develop severe complications following 
this type of complex surgery (26). 
This meta-analysis suggested long-term survival 
following salvage esophagectomy was equivalent to 
NCRS. However, it must be acknowledged that the 
overall treatment pathway of giving patients definitive 
chemoradiotherapy with follow-up salvage esophagectomy 
remains unexamined within the current published literature 
as the denominator of patients remains unquantified. 
The proportion of patients with persistent or recurrent 
disease and not considered for salvage esophagectomy 
due to disease progression or poor patient physiology 
remains unknown, and therefore the overall efficacy of this 
treatment approach cannot be fully examined. Further, as 
described above the majority of included studies grouped 
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Odds ratio meta-analysis plot [random effects]
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Smither 0.95 (0.25, 3.82)
Nakamura 1.71 (0.35, 9.35)
Morita 2.44 (0.84, 6.50)
Miyata 1.31 (0.47, 3.38)
Marks 1.38 (0.69, 2.63)
Markar 1.07 (0.77, 1.49)
Farinella 1.53 (0.35, 6.45)
Chao 0.11 (0.02, 0.49)
combined [random] 1.24 (0.83, 1.86)
odds ratio (95% confidence interval)
Odds ratio meta-analysis plot [random effects]
0.1 0.2 0.5 1 2 5 10 100 1000
Tomimaru 3.83 (0.75, 25.21)
Tacheuchi 0.86 (0.20, 3.39)
Nakamura 0.77 (0.22, 2.67)
Morita 1.42 (0.50, 3.68)
Miyata 1.05 (0.23, 3.75)
Marks 1.79 (0.58, 4.65)
Markar 1.17 (0.70, 1.97)
Farinella 7.15 (0.50, 387.30)
Chao 1.14 (0.32, 4.11)
combined [random] 1.29 (0.94, 1.76)
odds ratio (95% confidence interval)
Figure 6 Forrest plot showing no significant difference between the groups in pulmonary complications (POR =1.24; 95% CI, 0.83–1.86, 
P=0.292). POR, pooled odds ratios.
Figure 7 Forrest plot showing no significant difference between the groups in positive resection margin incidence (POR =1.29; 95% CI, 
0.94–1.76, P=0.114). POR, pooled odds ratios.
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both persistent and recurrent disease together. Previous 
investigations (15), have suggested that persistent disease 
following definitive chemoradiotherapy may represent a 
more biological aggressive variant of esophageal cancer. 
Thus, future studies and treatment recommendations must 
attempt to distinguish these two distinct patient groups who 
may both be eligible to receive salvage esophagectomy, but 
may have a substantially different prognosis. 
In conclusion, salvage esophagectomy following 
definitive chemoradiotherapy appears to have comparable 
outcomes to NCRS and planned esophagectomy in terms of 
short- and long-term mortality. However anastomotic leak 
is increased following salvage esophagectomy indicating 
the complexity of this procedure, and the need for this to 
be performed in carefully selected patients, within specialist 
esophageal cancer centers and by high volume experienced 
esophageal cancer surgeons.
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